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Mean progression-free survival was 6.2 months (range: 2-11). Four patients are still alive with a median follow-up of 11 months
(range: 2-15) Conclusion; As a result, LC treatment in patients of c-erbB2 + metastatic breast cancer along with brain metastases
may be considered as an effective and tolerable treatment option.
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Introduction: Many patients with cancer have depression and anxiety disorder and need to psychiatry treatment. Telepsychiatry is an
appropriate and cost-savings option for accessibility to specialists. Telepsychiatry is use of telemedicine and communication
technology in mental health service delivery and psychiatric consultation. Telepsychiatry provides increased access to services and
has helped enhance the provision of services to patients in any time and anywhere. Aim of this study is telepsychiatry as the effective
intervention for improving cancer care. Methods and materials: This study is review survey. Data was gathered from valid medical
data base. Results: This review survey opportunities, challenges and ethics issue of application of telepsychiatry in enhancing care in
patients with cancer. Conclusions: literatures show telepsychiatry is effective approach for decreasing anxiety, distress and
depression levels. Counseling in telepsychiatry increase quality of life of patients. With attention to long period of cancer; this manner
is cost benefit method for treatment mental health of these patients.
P-234 PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA IN ADULTS: A SINGLE CENTER
EXPERIENCE
N. Babacan, D. Uncu, O. Oksuzoglu, S. Cihan, H. Odabas, M. Seker, N. Kandemir, N. Ozdemir, B. Civelek, N. Zengin
Ankara Numune Training and Research Hospital, Department of Medical Oncology
INTRODUCTION: Primary central nervous system lymphoma (PCNSL) is an extremely rare subgroup of non-Hodgkin lymphoma
(NHL). Individuals who are immunosuppressed such as patients with AIDS or those taking certain drugs after organ transplantation,
appear to be at increased risk for PCNSL. We analysed clinical characteristics treatment and survival of PCNSL patients who was
admitted to our clinic, retrospectively. METHOD: Between November 2001 and December 2009, 9 patients were diagnosed as
PCNSL. Survival rates were analysed with Kaplan- Meier method (SPSS version 13.0). RESULTS: Nine (0.1.%) of whole 598 NHL
patients were diagnosed as PCNSL. Median age was 58 (35-75) years. None of them had suffered from immunosuppresive
background like AIDS, radiotherapy, organ transplantation etc. The most common symptom was headache (n=4), and the most
common location was frontal lobe (n=5). The histology of all patients was diffuse large B-cell lymphoma. Four patients were treated
with radiotherapy and chemotherapy and two patients with only chemotherapy. While 4 patients had been given high dose
methotrexate (>2.5 gr/m2), 2 patients had been given methotrexate and cytosine arabinoside combination. The median follow-up was
7.5 (2-76) months. Median overall survival was 10 months (2-74). CONCLUSION: Despite of using multi-modality treatment
strategies, PCNSL patients has still have a poor prognosis.
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Introduction: Ewing sarcoma family tumors (Ewing sarcoma and primitive neuroectodermal tumor) are the second most common
primary bone tumors seen in childhood and adolescence and consists of 10% of primary bone tumors. The aim of treatment in Ewing
sarcoma is while to cure the disease and also to protect functions and to minimise the sequels can be emerged at the long-
time.Purpose: The aim of this study is to analyse treatments of patients with Ewing sarcoma family of tumors that were diagnosed
histopathologically in our institute.Patients: In this study we evaluated 34 patients with Ewing sarcoma family of tumors treated in our
hospital between 2001-2008. Age range was 14-38, median age 23.17, M:F ratio was 27:7.Results: In 13 of 34 patients primary
tumor localisation was axial sceletal system (spine, pelvis), in the others was extremities. Eleven patients had metastatic disease at
the onset of diagnosis. Fourteen patients had undergone surgery to get local control of disease. Totally 33 patients received
chemotherapy according to the National Cancer Institute(NCI) protocol. Only fourteen patients could complete fifty-one weekly
treatment. 25 of 33 patients were administered radiotherapy aimed for local control, 4 patients were administered palliative
radiotherapy.Finally, in the treatment of total 18 of 33 patients with Ewing sarcoma family of tumors achievement has employed.
Discussion: The best result in the treatment of Ewing sarcoma family of tumors can be achieved with close collaboration between the
experienced members of the team of the treatment. In this retrospective study we made a treatment plan with multidiciplinary
approach of the teams of medical oncology, radiation oncology and surgeries( orthopedia, neurochirurgia and reconstructive
surgery). Because Ewing sarcoma is a systemic disease, micrometastases must be considered to be existed at the onset of the
diagnosis of disease. Systemic chemotherapy is effective in the treatment of microscopic and macroscopic disease and also lessen
tumor volume. Downsizing of tumor volume increases the efficacy of treatment methods of local control including radiotherapy and
surgical resection. And it must not allowed for local control methods to delay systemic chemotherapy because failure of the treatment
always is depended on existing of distant metastases.
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Introduction:Papillary thyroid carcinoma accounts for approximately 85%of thyroid tumors.According to the World Health
Organization, papillary microcarcinoma of the thyroid(PTMC)is defined as a papillary thyroid carcinoma(PTC) measuring 10 mm in
the greatest dimension.Methods:Between 2005 and 2008,30 patients with PTMC have been treated and the records of these patients
were reviewed retrospectively.Results:The mean age was 45.3(25-67)years in patients with PTMC [23(76.6%)women and
7(23.3%)men].Total thyroidectomy and near-total thyroidectomy in 26(86.6%) patients and subtotal thyroidectomy in 4
(13.3%)patients were performed.In 9(30%)of the patients the tumor was multifocal.Extrathyroidal invasion were found in
